Spark Investment Management LLC increased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 56.3% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 46,100 shares of the biotechnology company’s stock after purchasing an additional 16,600 shares during the quarter. Spark Investment Management LLC owned 0.11% of United Therapeutics worth $5,216,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in UTHR. Legacy Financial Advisors Inc. bought a new position in United Therapeutics in the second quarter valued at about $107,000. NuWave Investment Management LLC lifted its holdings in United Therapeutics by 13,112.5% in the first quarter. NuWave Investment Management LLC now owns 1,057 shares of the biotechnology company’s stock valued at $116,000 after acquiring an additional 1,049 shares during the period. HL Financial Services LLC lifted its holdings in United Therapeutics by 40.2% in the first quarter. HL Financial Services LLC now owns 2,053 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 589 shares during the period. Trexquant Investment LP bought a new position in United Therapeutics in the first quarter valued at about $266,000. Finally, Fox Run Management L.L.C. bought a new position in United Therapeutics in the second quarter valued at about $269,000. 99.59% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms have weighed in on UTHR. Barclays reissued a “sell” rating and issued a $100.00 target price on shares of United Therapeutics in a report on Thursday, August 2nd. Cowen reaffirmed a “hold” rating and issued a $110.00 price objective on shares of United Therapeutics in a research note on Thursday, August 2nd. HC Wainwright set a $95.00 price objective on United Therapeutics and gave the stock a “hold” rating in a research note on Monday, August 13th. Credit Suisse Group downgraded United Therapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, August 8th. Finally, TheStreet raised United Therapeutics from a “c+” rating to a “b” rating in a research note on Thursday, August 16th. Two analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. United Therapeutics currently has a consensus rating of “Hold” and an average target price of $138.86.

NASDAQ:UTHR opened at $125.03 on Tuesday. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.64 and a quick ratio of 4.35. United Therapeutics Co. has a 12-month low of $100.57 and a 12-month high of $152.55. The stock has a market cap of $5.47 billion, a P/E ratio of 11.48, a price-to-earnings-growth ratio of 29.08 and a beta of 1.28.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, August 1st. The biotechnology company reported $3.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $1.41. United Therapeutics had a return on equity of 34.42% and a net margin of 40.87%. The firm had revenue of $444.50 million during the quarter, compared to analysts’ expectations of $368.63 million. During the same quarter last year, the business posted $4.37 earnings per share. The firm’s revenue was up .0% on a year-over-year basis. research analysts anticipate that United Therapeutics Co. will post 14.4 EPS for the current year.

In other United Therapeutics news, Director Richard Giltner sold 3,240 shares of the firm’s stock in a transaction that occurred on Thursday, August 16th. The stock was sold at an average price of $129.38, for a total transaction of $419,191.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Judy D. Olian sold 600 shares of the firm’s stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $112.38, for a total value of $67,428.00. The disclosure for this sale can be found here. Insiders have sold a total of 7,080 shares of company stock valued at $852,966 in the last 90 days. 8.20% of the stock is currently owned by company insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Recommended Story: Average Daily Trade Volume – ADTV

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.